VivoSeq
Other

Testosterone

0

Pipeline Programs↗

11

Active Trials↗

15

Companies Involved↗

Testosterone is an early-stage landscape with 0 programs across 15 companies. The most active players are Clarus Therapeutics, Inc., Eli Lilly, Acerus Pharmaceuticals Corporation.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

84/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Clarus Therapeutics, Inc.

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalA

Acerus Pharmaceuticals Corporation

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalS

Solvay Pharmaceuticals

0 programs

PreclinicalGSK logo

GSK

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

164

clinical trials

Completed119 · 73%
Unknown status12 · 7%
Terminated11 · 7%
Withdrawn11 · 7%
Recruiting5 · 3%
Not yet recruiting5 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

164 trials

Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT07142551·60 enrolled
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04363164·150 enrolled
Testosterone and Neural Function
Recruiting·VVA Office of Research and Development·Phase 1·NCT06130449·15 enrolled
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT07476001·12 enrolled
Puberty, Testosterone, and Brain Development
Recruiting·UUniversity of Colorado, Denver·N/A·NCT06670053·100 enrolled
Sexual Effects of Transdermal or Vaginal Testosterone
Active, not recruiting·UUniversity of Sao Paulo General Hospital·Phase 2·NCT06794346·132 enrolled
TRAP Study: Testosterone for Androgen Receptor Polymorphism
Not yet recruiting·IInstituto Bernabeu·Phase 4·NCT06195163·100 enrolled
The Role of Estrogen and Testosterone in Determining Brain Blood Flow and Metabolic Regulation in Humans
Not yet recruiting·UUniversity of British Columbia·N/A·NCT07212712·50 enrolled
Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17
Not yet recruiting·UUniversity of Washington·Phase 1/2·NCT06312761·10 enrolled
A Dose Ranging Study to Examine TDS-Testosterone 5%
Not yet recruiting·TTransdermal Delivery Solutions Corp·Phase 2·NCT01894308·48 enrolled
Peri-Operative Testosterone Administration in Primary Hip Arthroscopy
Not yet recruiting·AAmerican Hip Institute·Phase 4·NCT06462482·60 enrolled
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
Completed·CClarus Therapeutics, Inc.·Phase 3·NCT01699178·182 enrolled
Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
Completed·LLipocine Inc.·Phase 3·NCT03242590·95 enrolled
A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)
Completed·Merck & Co. logoMerck & Co.·Phase 1·NCT00816712·28 enrolled
Testosterone MD-Lotion Residual Washing Study
Completed·AAcrux DDS Pty Ltd·Phase 1·NCT00996151·10 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)